Thalidomide responsiveness in an infant with Behçet's syndrome

Area of Science:

• Immunology
• Rheumatology
• Pediatrics

Background:

• Behçet's syndrome is a chronic, relapsing vasculitis affecting multiple organ systems.
• Key features include oral aphthous stomatitis, genital ulcerations, and uveitis.
• It is a multisystemic inflammatory disease with potential neurological, vascular, and dermatological manifestations.

Observation:

• A case study involving an infant diagnosed with Behçet's syndrome is presented.
• The infant exhibited resistance to standard immunosuppressive therapies, including high-dose corticosteroids and cytotoxic agents.
• Conventional treatments failed to alleviate the infant's symptoms effectively.

Findings:

• Thalidomide, an immune response-modifying agent, was administered to the infant.
• The infant demonstrated significant clinical improvement and symptom resolution following thalidomide treatment.
• This suggests thalidomide's efficacy in managing refractory Behçet's syndrome.

Implications:

• The findings support exploring thalidomide as a therapeutic option for Behçet's syndrome.
• It is particularly relevant for patients unresponsive to established immunosuppressive treatments.
• Further investigation into thalidomide's role in Behçet's syndrome management is warranted, especially in pediatric cases.